Atossa Therapeutics Q2 2023 net loss $9.8M; clinical enrollment milestones; CFO appointed

ATOSSA THERAPEUTICS, INC.

2024-Q2 EPS reported -$0.13

Cash at June 30, 2023: $99.4M, down from $110.9M at Dec 31, 2022.
Net loss Q2 2023: $9.83M vs $6.67M Q2 2022; operating expenses $7.79M up 18% YoY.
Impairment charge of $2.99M on investment in Dynamic Cell Therapeutics (DCT).
Phase 2 EVANGELINE PK cohort fully enrolled; Karisma-Endoxifen 70% enrolled; I-SPY 2 30% enrolled.
Appointed Greg Weaver as CFO; US patent granted for enterically encapsulated endoxifen.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ATOSSA THERAPEUTICS, INC. reported the quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $9,830.

Period: the quarter ended June 30, 2023
Net income: Net loss for the second quarter of 2023 was $9,830
Result: reported results

Exact text from the filing

On August 14, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended June 30, 2023 financial results and a Company update.

View on SEC.gov

Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-023423

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.